ONC
BeOne Medicines Ltd.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 30 ▲ 3 funds open new positions (13F)
- Jul 13 ▲ Jefferies upgrades
- Aug 10 ▼ Chairman and CEO John Oyler filed a Form 144 on August 10, 2026, sig…
- Aug 10 Trial readout: Results Pending: Tislelizumab (Phase 3), Completed 79d ago
- Aug 11 Trial readout: Results Pending: Tislelizumab (Phase 3), Completed 80d ago
- Aug 14 ▼ Short interest jumps 44.9% to 1.28M
- Sep 8 ▼ 1 insider sell $13.0M at $349.22
- Sep 28 to Sep 30 ▼ 2 days of insider sells: $11.7M by 2 insiders, avg $365.14
- Oct 13 ▼ 1 insider sell $10.9M at $350.99
- Oct 27 ▼ 1 insider sell $11.3M at $362.97
- Nov 5 to Nov 6 ▼ 2 days of insider sells: $1.1M by 2 insiders, avg $403.59
- Nov 5 ▲ BeOne Medicines reported Q3 2026 total revenue of $1.89B (+34% YoY)…
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $47.9M.
- InstitutionsBULLISH
Q2 2026: 30 added (3 new), 16 trimmed or exited. Largest new: Qube Research & Technologies $23.2M, Life Cycle Investment Partners $20.8M.
- AnalystsBULLISH
10 of 11 rate it Buy or better. Median target $468.62 (+14%).
- Short sellersSTEADY
Short interest −10.6% to 1.60M shares. 4.4 days to cover, ≈1.4% of shares.
- TrendUPTREND
11% above its 50-day average. New closing high $424.00 on Nov 10.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | TRIM | $706.3M |
| Capital World Investors | ADD | $641.1M |
| CITADEL ADVISORS LLC | ADD | $406.2M |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | $216.2M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | $154.8M |
| Man Group plc | ADD | $87.6M |
| UBS Group AG | TRIM | $73.7M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $71.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is inside the target range. Median implies +14%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 6, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 6, 2026 | Truist Securities REITERATE | Buy |
| Nov 6, 2026 | Barclays MAINTAIN | Overweight |
| Nov 6, 2026 | Citizens MAINTAIN | Market Outperform |
| Nov 6, 2026 | Wells Fargo MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Wang Xiaodong Director Nov 9, 2026 | GIFT | 1,183 sh |
Ball Titus B. Principal Accounting Officer Nov 6, 2026 | EXERCISE | $182.6K |
Ball Titus B. Principal Accounting Officer Nov 6, 2026 | EXERCISE | $108.0K |
Ball Titus B. Principal Accounting Officer Nov 6, 2026 | EXERCISE | 8,827 sh |
Ball Titus B. Principal Accounting Officer Nov 6, 2026 | SELL | $621.7K |
Ball Titus B. Principal Accounting Officer Nov 6, 2026 | SELL | $10.6K |
Ball Titus B. Principal Accounting Officer Nov 6, 2026 | EXERCISE | 11,440 sh |
Lee Chan Henry SVP, General Counsel Nov 5, 2026 | SELL | $182.9K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
27 filings · 3 bullish · 4 bearish · 1 mixed · 19 neutral- NEUTRAL SC 13G/ANov 13, 2026
CEO John Oyler filed an amended Schedule 13G reporting beneficial ownership of 54,065,077 ordinary…
Monitor for any future conversion to Schedule 13D if Oyler shifts to activist stance, but this filing is a routine passive update with no immediate trading signal.
- NEUTRAL CLUSTERNov 10, 2026
Two BeOne Medicines insiders sold a combined $805K in open-market sales within a week of the…
The sales are small and include a planned 10b5-1 trade, so no bearish signal. Monitor for any larger unplanned sales by C-suite executives in coming weeks.
- NEUTRAL 144Nov 6, 2026
Titus B. Ball, an officer of BeOne Medicines Ltd., filed a Form 144 notice of intent to sell 1,559…
The filing is a routine insider sale notice with immaterial size. Monitor for any pattern of larger insider sales in future filings, but this single notice carries no actionable signal.
- NEUTRAL 144Nov 5, 2026
Chan Lee, an officer of BeOne Medicines Ltd., filed a Form 144 notice of intent to sell 1,115 ADSs…
The sale is small relative to market cap and executed under a pre-arranged 10b5-1 plan, reducing the likelihood of opportunistic insider selling. Monitor for any acceleration of insider sales or…
All ONC filing & press-release reports (27)
- SC 13G/A reportNov 13, 2026
- CLUSTER reportNov 10, 2026
- 144 reportNov 6, 2026
- 144 reportNov 5, 2026
- 8-K reportNov 5, 2026
- INST-CLUSTER reportNov 4, 2026
- CLUSTER reportOct 2, 2026
- INST-CLUSTER reportSep 22, 2026
- CLUSTER reportSep 10, 2026
- CLUSTER reportSep 3, 2026
- 8-K reportAug 26, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 12, 2026
- 144 reportAug 10, 2026
- CLUSTER reportAug 5, 2026
- 8-K reportAug 5, 2026
- CLUSTER reportJul 24, 2026
- CLUSTER reportJul 17, 2026
- CLUSTER reportJul 14, 2026
- 144 reportJun 23, 2026
- CLUSTER reportJun 15, 2026
- CLUSTER reportJun 10, 2026
- CLUSTER reportJun 10, 2026
- 144 reportJun 11, 2026
- CLUSTER reportJun 10, 2026
- CLUSTER reportMay 27, 2026
- 8-K reportFeb 26, 2026